Apellis Pharmaceuticals’ (APLS) “Sector Perform” Rating Reaffirmed at Royal Bank of Canada

Royal Bank of Canada reiterated their sector perform rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a research note published on Monday morning, Benzinga reports. The brokerage currently has a $25.00 price target on the stock.

APLS has been the topic of a number of other reports. JPMorgan Chase & Co. lowered their target price on Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating on the stock in a research note on Friday, September 13th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $80.00 price target on shares of Apellis Pharmaceuticals in a report on Wednesday, July 31st. HC Wainwright lowered their price objective on shares of Apellis Pharmaceuticals from $92.00 to $83.00 and set a “buy” rating on the stock in a research report on Friday, August 2nd. William Blair started coverage on Apellis Pharmaceuticals in a research note on Wednesday, October 16th. They issued an “outperform” rating for the company. Finally, Robert W. Baird decreased their price objective on shares of Apellis Pharmaceuticals from $96.00 to $92.00 and set an “outperform” rating for the company in a report on Monday, September 23rd. Five research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $65.41.

Apellis Pharmaceuticals Trading Up 2.1 %

NASDAQ APLS opened at $28.56 on Monday. The company has a quick ratio of 4.18, a current ratio of 5.08 and a debt-to-equity ratio of 1.73. Apellis Pharmaceuticals has a 52 week low of $26.28 and a 52 week high of $73.80. The company has a market cap of $3.48 billion, a price-to-earnings ratio of -10.42 and a beta of 0.87. The business has a 50 day moving average price of $31.81 and a 200-day moving average price of $37.40.

Insider Transactions at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the completion of the transaction, the director now directly owns 100,000 shares of the company’s stock, valued at approximately $3,623,000. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 6.80% of the company’s stock.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Wolverine Asset Management LLC purchased a new position in Apellis Pharmaceuticals in the third quarter valued at about $27,000. Capital Performance Advisors LLP acquired a new position in Apellis Pharmaceuticals during the 3rd quarter worth approximately $56,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Apellis Pharmaceuticals in the 1st quarter worth about $89,000. nVerses Capital LLC boosted its holdings in Apellis Pharmaceuticals by 300.0% in the second quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock worth $107,000 after purchasing an additional 2,100 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Apellis Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after buying an additional 781 shares during the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).